Read by QxMD icon Read


A Momen, M Ali, P K Karmakar, M Z Ali, A Haque, M R Khan, M I Khalil, M S Hossain, R M Huda, M N Goni
BACKGROUND: Ischemic cardiomyopathy is a growing burden in third world countries. So far, benefits of trimetazidine in this group of patients have been suggested by clinical trials mainly conducted in Europe. We evaluated the effect of trimetazidine on ischemic dilated cardiomyopathy in our population. METHODS AND RESULTS: 98 patients (aged 58.5±9.2 years), admitted with decompensated heart failure with previous history of MI and/or documentation of significant CAD with previous CAG, were chosen for the study...
November 2016: Indian Heart Journal
Suman Jatain, Aditya Kapoor, Archana Sinha, Roopali Khanna, Sudeep Kumar, Naveen Garg, Satyendra Tewari, Pravin Goel
OBJECTIVES: To study the role of metabolic modulator (trimetazidine: TMZ) in dilated cardiomyopathy (DCM). Optimizing altered substrate metabolism in heart failure (HF) with metabolic modulators allows more efficacious energy production from glucose than from free fatty acids. METHODS: 100 patients of DCM (47.7 years, NYHA class 2.17, LVEF 27.3%) were randomized to TMZ (20mg tid, n=50) vs conventional therapy (n=50). Functional status, BNP and various echocardiographic parameters were assessed at 3-6 months...
November 2016: Indian Heart Journal
Yuanyuan Ke, Dingli Xu, Minxiong Li, Zenglong Wu, Yongpeng Huang
OBJECTIVE: To evaluate the effects of bisoprolol combined with trimetazidine on the treatment of heart failure patients having concomitant chronic obstructive pulmonary disease (COPD); in comparison with control group treated with standard therapy only. METHODS: A total of 120 heart failure patients having concomitant COPD were selected and randomly divided into a control group and a treatment group according to different treatment methods (n=60). The control group was given continuous low flow oxygen inhalation and inotropic agents, and their cardiac stress was also reduced...
September 2016: Pakistan Journal of Medical Sciences Quarterly
Ailan Chen, Wanglin Li, Xinyu Chen, Yuechun Shen, Wenjun Dai, Qi Dong, Xinchun Li, Caiwen Ou, Minsheng Chen
BACKGROUND: Metabolism remodeling has been recognized as an early event following cardiac pressure overload. However, its temporal association with ventricular hypertrophy has not been confirmed. Moreover, whether trimetazidine could favorably affect this process also needs to be determined. The aim of the study was to explore the temporal changes of myocardial metabolism remodeling following pressure-overload induced ventricular hypertrophy and the potential favorable effect of trimetazidine on myocardial metabolism remodeling...
November 17, 2016: BMC Cardiovascular Disorders
Ali Ayyildiz, Sema Nur Ayyildiz, Erdal Benli, Havva Erdem, Selma Cirrik, Tevfik Noyan, R Cankon Germiyanoglu, Abdullah Çirakoglu
OBJECTIVES: We aimed to study the effect of trimetazidine (TMZ) on urethral wound repair. MATERIALS AND METHODS: A total of 52 male rats were used; 8 groups were formed: 1-week and 3-week control (C1, C3), sham (S1, S3), oral (OT1, OT3), and intraurethral TMZ (IUT1, IUT3) groups. Serum and urine total antioxidant capacity (TAC), total oxidant capacity (TOC), and 8-hydroxy-deoxy-guanosine (8-OHdG) were studied. Hematoxyline-Eosin was used for the histopathological study...
September 2016: Iranian Journal of Basic Medical Sciences
Lei Zhang, Wen-Yuan Ding, Zhi-Hao Wang, Meng-Xiong Tang, Feng Wang, Ya Li, Ming Zhong, Yun Zhang, Wei Zhang
No abstract text is available yet for this article.
November 1, 2016: Journal of Translational Medicine
Cher-Rin Chong, Gao J Ong, John D Horowitz
Angina pectoris, or symptomatic myocardial ischaemia, reflects an impairment of coronary blood flow, and usually a deficiency of available myocardial energetics. Treatment options vary with the precise cause, which may vary with regards to the roles of increased myocardial oxygen demand versus reduced supply. Traditionally, organic nitrates, β-adrenoceptor antagonists, and non-dihydropyridine calcium antagonists were the only commonly used prophylactic anti-anginal agents. However, many patients failed to respond adequately to such therapy, and/or were unsuitable for their use...
December 2016: Expert Opinion on Emerging Drugs
Georgia Kourlaba, George Gourzoulidis, George Andrikopoulos, Konstantinos Tsioufis, Alexandra Beletsi, Nikos Maniadakis
BACKGROUND: To evaluate the cost-effectiveness of trimetazidine (TMZ) as add-on therapy to standard-of-care (SoC) compared to SoC alone in patients with chronic stable angina who did not respond adequately to first line therapy with b-blockers, nitrates or calcium channel antagonists in Greece. METHODS: A Markov model with 3-month cycles and 1-year time horizon was developed to assess the comparators. The analysis was conducted from a third-party payer perspective...
September 27, 2016: BMC Health Services Research
Ning Ma, Jingyun Bai, Weihua Zhang, Hong Luo, Xin Zhang, Donghai Liu, Chenhui Qiao
Trimetazidine is a piperazine-derived metabolic agent, which exerts cell protective effects and has been reported to be efficient in the treatment of chronic stable angina pectoris. In addition, it has been shown to exert protection against acute myocardial infarction. The present study aimed to investigate whether trimetazidine protects against cardiac ischemia/reperfusion (I/R) injury, and to determine whether its curative effects are associated with microRNA (miRNA)‑21 expression, Akt, and the B‑cell lymphoma 2 (Bcl‑2)/Bcl‑2‑associated X protein (Bax) pathway...
November 2016: Molecular Medicine Reports
Filomena S G Silva, Rui F Simões, Renata Couto, Paulo J Oliveira
BACKGROUND: Cardiovascular diseases (CVDs) are one of the main factors responsible for human morbidity and mortality. Since mitochondria play a critical role in the regulation of cardiac tissue homeostasis, this organelle is a critical target for the protective effects of several pharmaceuticals. Although specific mitochondria-targeted antioxidants and some pharmacological agents are described as potential cardioprotective agents, there are still a few effective mitochondrial therapies for the treatment of CVDs...
August 22, 2016: Current Pharmaceutical Design
Cian P McCarthy, Kieran V Mullins, David M Kerins
With evidence for efficacy in such diverse clinical settings such as stable coronary artery disease, reperfusion injury, and contrast-induced nephropathy, trimetazidine (TMZ) is novel among cardiovascular agents. In spite of this and almost half a century of clinical experience with the drug, it remains licensed only as an adjunct in the management of angina pectoris in patients who are inadequately controlled by or intolerant to first-line therapies. Although no single pharmacological mechanism has been hitherto universally accepted, TMZ is known to target deranged cellular energetics particularly in ischaemic myocardial tissue...
October 2016: European Heart Journal. Cardiovascular Pharmacotherapy
Asma Mahfoudh Boussaid, Rabi Selmi, Mohamed Bejaoui, Kaouther Hadj Ayed, Mohamed Amine Zaouali, Hassen Ben Abdennebi
BACKGROUND/AIM: The aim of this study was to compare the effects of single and repeated trimetazidine (TMZ) administration against warm hepatic ischemia/reperfusion (I/R) injury and to explore the possible mechanisms affected by TMZ. MATERIALS AND METHODS: Wistar rats were divided into 4 groups (n = 6). Sham: rats were subjected to dissection. I/R: rats were subjected to 60 min of partial hepatic ischemia followed by 24 h of reperfusion. TMZ1: Same as I/R group but rats were pretreated with a single dose of TMZ (10 mg/kg, intraperitoneal injection) 30 min before warm ischemia...
2016: Turkish Journal of Medical Sciences
Mayer Bassan
No abstract text is available yet for this article.
July 21, 2016: New England Journal of Medicine
Maria M Wanitschek, Jakob Dörler, Hannes F Alber
No abstract text is available yet for this article.
July 21, 2016: New England Journal of Medicine
E Magnus Ohman
No abstract text is available yet for this article.
July 21, 2016: New England Journal of Medicine
Hui Li, Fu-Yuan Liu, Xiao-Lan Li, Xiao-Mei Li, Lei Zhu
The aim of the study was to compare the clinical effects of carvedilol and trimetazidine for the treatment of alcoholic cardiomyopathy. A total of 60 patients diagnosed with alcoholic cardiomyopathy were enrolled in the study. The patients were randomly divided into the carvedilol (n=20), trimetazidine (n=20) and control (n=20) groups. The patients in the control, carvedilol and trimetazidine groups were treated with conventional drugs, conventional drugs + carvedil and conventional drugs + trimetazidine respectively, for 12 weeks...
August 2016: Experimental and Therapeutic Medicine
Yongyong Li, Dewei Wang, Chunxiao Hu, Peng Zhang, Dongying Zhang, Shu Qin
BACKGROUND: Several lines of evidence support the clinical use of trimetazidine as an adjunctive therapy in cardioischemic patients. Therefore, we assessed here the efficacy and safety of adjunctive trimetazidine therapy in acute myocardial infarction (MI) patients by a systematic review and meta-analysis of the current literature. METHODS: PubMed, the Cochrane Library, and the China National Knowledge Infrastructure databases were searched for clinical studies comparing adjunctive trimetazidine therapy against placebo in adult acute MI patients...
July 15, 2016: Cardiology
Khalid I Amber, Najah R Hadi, Bashaer M Muhammad-Baqir, Dina A Jamil, Hayder A Al-Aubaidy
BACKGROUND: This study aims to investigate the inflammatory response in Novolimus bioresorbable coronary scaffold implantation after a course treatment with trimetazidine (35mg tablet/twice daily for 4days). METHODS: This was a randomized single blind study. Forty diabetic patients with critical coronary stenosis were subjected to elective coronary scaffold implantation in Al-Najaf Center for Cardiac Surgery and Trans-Catheter Therapy, Najaf, Iraq, between January and July 2015...
October 1, 2016: International Journal of Cardiology
Nagla A El-Sherbeeny, Ghalia M Attia
Nephrotoxicity is a dose-limiting side effect of cisplatin (CSP). The study investigated the possible protective role of trimetazidine (TMZ) against CSP-induced nephrotoxicity in rats. Rats were divided into four groups; control, TMZ, CSP, and CSP + TMZ. The CSP group showed significant deterioration in kidney function with structural changes in the form of interstitial hemorrhage, glomeruli shrinkage and peritublar capillary congestion, tubular cells vacuolation, pyknosis, shedding and necrosis, and inflammatory cell infiltrates, all indicating renal damage...
July 2016: Canadian Journal of Physiology and Pharmacology
Mehmet Yaman, Uğur Arslan, Hasan Ali Gümrükçüoğlu, Musa Şahin, Hakkı Şimşek, Serkan Akdağ
BACKGROUND AND OBJECTIVES: Studies reveal that the microvolt T wave alternans (MTWA) test has a high negative predictive value for arrhythmic mortality among patients with ischemic or non-ischemic cardiomyopathy. In this study, we investigate the effects of trimetazidine treatment on MTWA and several echocardiographic parameters in patients with stable coronary artery disease. SUBJECTS AND METHODS: One hundred patients (23 females, mean age 55.6±9.2 years) with stable ischemic heart disease were included in the study group...
May 2016: Korean Circulation Journal
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"